AI
By
Is Exscientia Setting the Financial Benchmark for AI Drug Discovery with $6B+ in Pharma Commitments?
Strategic Insights Exscientia has emerged as one of the most financially validated AI-drug discovery companies, translating computational precision…
Is Insilico Medicine Redefining Drug Discovery as AI Becomes Core to Biopharma Strategy?
Executive Summary Insilico Medicine has emerged as one of the most influential AI-native biotechnology companies, reshaping how the…
Can Vanda Pharma’s FDA Approval of Nereus Unlock a New Growth Chapter in Motion-Sickness Treatment?
New York | Jan, 2026 — Vanda Pharmaceuticals Inc. achieved a major regulatory and commercial milestone after the…
Can Bristol Myers Squibb’s $330 Million AI Investment in 2025 — Powered by Strategic Partnerships — Accelerate Discovery, R&D and Commercial Impact in 2026?
Global – December 31, 2025 — Bristol Myers Squibb (BMS) significantly expanded its commitment to artificial intelligence (AI)…
Are AI Healthcare Tools Raising Ethical and Access Concerns?
January 26, 2026 | AI in Healthcare | Ethics, Equity & Policy Recent commentary in leading medical and…
Is “ChatGPT for Doctors” Driving OpenEvidence’s $12 B Valuation Surge?
January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion OpenEvidence, the AI platform often…
